In this study, patients diagnosed with advanced lung adenocarcinoma harboring susceptible EGFR mutations and treated with EGFR-TKI were grouped based on CSD, and the PFS and OS were compared among the smoking subgroups. Here, EGFR is linked to lung adenocarcinoma.